The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Clinical Trial
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Actions of angiotensin II may contribute to the progression of heart failure despite treatment with currently recommended drugs. We therefore evaluated the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard therapy for heart failure. ⋯ Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy. However, the post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a beta-blocker raises concern about the potential safety of this specific combination.
-
Randomized Controlled Trial Clinical Trial
Fluconazole prophylaxis against fungal colonization and infection in preterm infants.
Invasive fungal infection is associated with substantial morbidity and mortality in preterm infants. We evaluated the efficacy of prophylactic fluconazole in preventing fungal colonization and invasive infection in extremely-low-birth-weight infants. ⋯ Prophylactic administration of fluconazole during the first six weeks of life is effective in preventing fungal colonization and invasive fungal infection in infants with birth weights of less than 1000 g.
-
Review Case Reports
Clinical practice. Lowering cardiac risk in noncardiac surgery.